917 results on '"O'Rourke, Robert A."'
Search Results
2. Postbariatric hypoglycemia: symptom patterns and associated risk factors in the Longitudinal Assessment of Bariatric Surgery study
3. The Pathophysiology of Obesity and Obesity-Related Disease
4. MDCT imaging in Spigelian hernia, clinical, and surgical implications
5. Cholesterol 25-hydroxylase (CH25H) as a promoter of adipose tissue inflammation in obesity and diabetes
6. The human type 2 diabetes-specific visceral adipose tissue proteome and transcriptome in obesity
7. Matrix density regulates adipocyte phenotype
8. Adipose METTL14‐Elicited N6‐Methyladenosine Promotes Obesity, Insulin Resistance, and NAFLD Through Suppressing β Adrenergic Signaling and Lipolysis
9. Adipose tissue and the physiologic underpinnings of metabolic disease
10. The Pathophysiology of Obesity and Obesity-Related Disease
11. Elucidating nanoscale mechanical properties of diabetic human adipose tissue using atomic force microscopy
12. Serum biomarkers of inflammation and adiposity in the LABS cohort: associations with metabolic disease and surgical outcomes
13. Obesity and Cancer
14. Weight loss independent changes in adipose tissue macrophage and T cell populations after sleeve gastrectomy in mice
15. Advanced glycation end-products regulate extracellular matrix-adipocyte metabolic crosstalk in diabetes
16. Adipose METTL14‐Elicited N6‐Methyladenosine Promotes Obesity, Insulin Resistance, and NAFLD Through Suppressing β Adrenergic Signaling and Lipolysis.
17. The Pathophysiology of Obesity and Obesity-Related Diseases
18. Lumican modulates adipocyte function in obesity-associated type 2 diabetes
19. Preoperative factors and 3-year weight change in the Longitudinal Assessment of Bariatric Surgery (LABS) consortium
20. Obesity and cancer: at the crossroads of cellular metabolism and proliferation
21. Single-nuclei Transcriptome of Human AT Reveals Metabolically Distinct Depot-Specific Adipose Progenitor Subpopulations
22. Barrett’s Esophagus with High-Grade Dysplasia
23. Differentiation and Metabolic Interrogation of Human Adipocytes
24. Reporting weight change: standardized reporting accounting for baseline weight
25. Inflammation, obesity, and the promise of immunotherapy for metabolic disease
26. Human CD206+ macrophages associate with diabetes and adipose tissue lymphoid clusters
27. Treatment Strategies for Women With Stable Angina
28. Diabetes-Specific Regulation of Adipocyte Metabolism by the Adipose Tissue Extracellular Matrix
29. Prevalence of Adverse Intraoperative Events during Obesity Surgery and Their Sequelae
30. Systemic inflammation and insulin sensitivity in obese IFN-γ knockout mice
31. Effectiveness of Percutaneous Coronary Intervention in Patients With Silent Myocardial Ischemia (Post Hoc Analysis of the COURAGE Trial)
32. Impact of Metabolic Syndrome and Diabetes on Prognosis and Outcomes With Early Percutaneous Coronary Intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) Trial
33. Postbariatric hypoglycemia: symptom patterns and associated risk factors in the Longitudinal Assessment of Bariatric Surgery study
34. Optimal medical therapy with or without percutaneous coronary intervention in women with stable coronary disease: A pre-specified subset analysis of the Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation (COURAGE) trial
35. The Pathophysiology of Obesity and Obesity-Related Diseases
36. Comparison of 30-day outcomes after non-LapBand primary and revisional bariatric surgical procedures from the Longitudinal Assessment of Bariatric Surgery study
37. β-Blocker use following myocardial infarction: Low prevalence of evidence-based dosing
38. Mitral Valve Prolapse With a Late-Systolic Regurgitant Murmur May Be Associated With Significant Hemodynamic Consequences
39. Optimal Medical Therapy With or Without Percutaneous Coronary Intervention for Patients With Stable Coronary Artery Disease and Chronic Kidney Disease
40. Impact of an Initial Strategy of Medical Therapy Without Percutaneous Coronary Intervention in High-Risk Patients From the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) Trial
41. Impact of Optimal Medical Therapy With or Without Percutaneous Coronary Intervention on Long-Term Cardiovascular End Points in Patients With Stable Coronary Artery Disease (from the COURAGE Trial)
42. Effect of Reversible Intermittent Intra-abdominal Vagal Nerve Blockade on Morbid Obesity: The ReCharge Randomized Clinical Trial
43. The EMPOWER Study: Randomized, Prospective, Double-Blind, Multicenter Trial of Vagal Blockade to Induce Weight Loss in Morbid Obesity
44. Obesity results in adipose tissue T cell exhaustion
45. Pathways to Severe COVID‐19 for People with Obesity
46. 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
47. Optimal Medical Therapy Is a Proven Option for Chronic Stable Angina
48. ACC/AHA 2008 Guideline Update on Valvular Heart Disease: Focused Update on Infective Endocarditis: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
49. Functional Lumen Imaging Probe to Assess Geometric Changes in the Esophagogastric Junction Following Endolumenal Fundoplication
50. Management Strategies for Internal Hernia after Gastric Bypass
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.